MX2020008343A - Vacunas para ser utilizadas en la prevencion o tratamiento de leishmaniasis. - Google Patents

Vacunas para ser utilizadas en la prevencion o tratamiento de leishmaniasis.

Info

Publication number
MX2020008343A
MX2020008343A MX2020008343A MX2020008343A MX2020008343A MX 2020008343 A MX2020008343 A MX 2020008343A MX 2020008343 A MX2020008343 A MX 2020008343A MX 2020008343 A MX2020008343 A MX 2020008343A MX 2020008343 A MX2020008343 A MX 2020008343A
Authority
MX
Mexico
Prior art keywords
leishmaniasis
vaccines
prevention
treatment
relates
Prior art date
Application number
MX2020008343A
Other languages
English (en)
Inventor
Strebut-Borschitz Esther Von
Stefan Tenzer
Kirsten Dietze-Schwonberg
Anja Schermann
Original Assignee
Univ Der Johannes Gutenberg Univ Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Der Johannes Gutenberg Univ Mainz filed Critical Univ Der Johannes Gutenberg Univ Mainz
Publication of MX2020008343A publication Critical patent/MX2020008343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a vacunas que comprenden un polipéptido o proteína que se selecciona a partir del grupo que consta de p54, Q4Q8Z6, Q4Q6L9, Q4QHT2, E9AE98 de Leishmania major, o un fragmento inmunológicamente efectivo de los mismos, para ser utilizadas en la prevención o tratamiento de leishmaniasis. La invención también se refiere a una composición farmacéutica que comprende dicha vacuna.
MX2020008343A 2018-02-08 2019-02-06 Vacunas para ser utilizadas en la prevencion o tratamiento de leishmaniasis. MX2020008343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18155693.7A EP3524266A1 (en) 2018-02-08 2018-02-08 Vaccine for use in the prevention or treatment of leishmaniasis
PCT/EP2019/052882 WO2019154841A1 (en) 2018-02-08 2019-02-06 Vaccines for use in the prevention of treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
MX2020008343A true MX2020008343A (es) 2020-12-07

Family

ID=61192686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008343A MX2020008343A (es) 2018-02-08 2019-02-06 Vacunas para ser utilizadas en la prevencion o tratamiento de leishmaniasis.

Country Status (4)

Country Link
EP (1) EP3524266A1 (es)
BR (1) BR112020014792A2 (es)
MX (1) MX2020008343A (es)
WO (1) WO2019154841A1 (es)

Also Published As

Publication number Publication date
WO2019154841A1 (en) 2019-08-15
EP3524266A1 (en) 2019-08-14
BR112020014792A2 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
ZA201904723B (en) Population-based immunogenic peptide identification platform
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
CL2019002134A1 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2016002154A (es) Vacuna contra el virus respiratorio sincitial.
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
AU2019205627B2 (en) MHC class I associated peptides for prevention and treatment of multiple flavi virus
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
PH12020551618A1 (en) Erenumab compositions and uses thereof
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
MX2020008343A (es) Vacunas para ser utilizadas en la prevencion o tratamiento de leishmaniasis.
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
MX2017001651A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
EP4275700A3 (en) Vaccine immunogens
EA201992057A1 (ru) Персонализированная платформа для идентификации иммуногенного пептида